about
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinibLung cancer signatures in plasma based on proteome profiling of mouse tumor modelsDevelopment of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitorsReduced NF1 expression confers resistance to EGFR inhibition in lung cancerAcquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1.MYCxing it up with FGFR1 in squamous cell lung cancer.Emerging Agents and New Mutations in EGFR-Mutant Lung CancerExpression of ERp29, an endoplasmic reticulum secretion factor in basal-cell carcinoma.Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors.Oncogene cooperation in tumor maintenance and tumor recurrence in mouse mammary tumors induced by Myc and mutant Kras.Myc is a Notch1 transcriptional target and a requisite for Notch1-induced mammary tumorigenesis in mice.DOK2 inhibits EGFR-mutated lung adenocarcinoma.A mouse model of uterine leiomyosarcomaModulation of notch signaling elicits signature tumors and inhibits hras1-induced oncogenesis in the mouse mammary epitheliumOptimizing the sequence of anti-EGFR-targeted therapy in EGFR-mutant lung cancer.Perfect ALKemy: optimizing the use of ALK-directed therapies in lung cancer.Isolation of epithelial, endothelial, and immune cells from lungs of transgenic mice with oncogene-induced lung adenocarcinomasNotch in mammary gland development and breast cancer.Lung cancer in the era of precision medicineTwo sides of the same coin: EGFR exon 19 deletions and insertions in lung cancer.Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomasLoss of MIG6 Accelerates Initiation and Progression of Mutant Epidermal Growth Factor Receptor-Driven Lung Adenocarcinoma.HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutationAfatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naïve EGFR L858R-Induced Lung AdenocarcinomaNoncovalent wild-type-sparing inhibitors of EGFR T790MA mouse plasma peptide atlas as a resource for disease proteomics.How genetically engineered mouse tumor models provide insights into human cancersOncogenic EGFR Represses the TET1 DNA Demethylase to Induce Silencing of Tumor Suppressors in Cancer Cells.Next-generation sequencing of paired tyrosine kinase inhibitor-sensitive and -resistant EGFR mutant lung cancer cell lines identifies spectrum of DNA changes associated with drug resistanceMutational landscape of EGFR-, MYC-, and Kras-driven genetically engineered mouse models of lung adenocarcinoma.De novo selection of oncogenes.Translational therapeutics in genetically engineered mouse models of cancer.Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells.ERBB3-independent activation of the PI3K pathway in EGFR-mutant lung adenocarcinomasDefective insulin secretion in pancreatic beta cells lacking type 1 IGF receptor.Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma.PD-1 Axis Inhibitors in EGFR- and ALK-Driven Lung Cancer: Lost Cause?The Impact of Smoking and TP53 mutations in lung adenocarcinoma patients with targetable mutations - the Lung Cancer Mutation Consortium (LCMC2).Increased EGFR Phosphorylation Correlates with Higher Programmed Death Ligand-1 Expression: Analysis of TKI-Resistant Lung Cancer Cell Lines.Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer.
P50
Q24561953-D68B964B-CF34-4006-BE3F-C588E0DCF82FQ24628852-67662053-BAD3-4747-A8A2-BB8B11E29859Q27302811-1DD00B25-5CB5-4C95-9E87-70944D1B41A4Q33572728-64EE576B-E80E-4E69-9828-401CE56653B1Q33819404-DED9C45C-54E2-4BF6-9418-DC6706AAEE59Q33820617-1CCB9F88-1B37-4082-AA59-540F292E7F79Q34484794-A498638B-63A3-4111-8892-4810FE18CADDQ34570486-E75521F5-3038-4B7F-8B5C-8CD2CDAF5E39Q34666826-1D8846DA-2AF4-48D0-BE75-7018619AE884Q34763792-2ACBBC6C-70A1-42DE-BA85-D25149DF1B2DQ35039989-492C07B6-6A86-4E7A-89AD-D9F070BCD7E9Q35047411-BFB54BD7-7969-421C-815A-C8942D73542AQ35083288-409018C6-0BCD-4E27-862E-EA3EB381390CQ35103047-5AD4CE1A-8402-47E6-8A56-44CBCC5E0C33Q35112467-87C3A738-9678-4C00-A33D-9BEFAC877E3DQ35461464-321CC50A-6206-4CA2-85DC-BB96786BE46AQ35816386-4E97DA8D-95A3-4407-A057-2994780FDC4FQ35853093-6EAF7554-929A-4960-AE38-C3B34F389333Q35861107-D7E45034-EFA1-4555-B0B0-8BE56A504BF0Q35896601-553EDDEF-EA76-4B3D-88A5-3FFDB3966C6DQ36026392-74FD5344-9449-4C83-AABD-4F70DBC3A552Q36028210-70930EF2-EE6B-42FA-A760-97C06B395D3CQ36322762-D1037584-D583-4869-AAA1-A7518A2656D5Q36471537-F3D5395A-C13A-4CF1-8DC8-4376E9162345Q36622817-6BD34E7E-5378-4E47-B9A8-659A89EE387FQ36787143-52C3130C-27DC-4B8B-9D4F-992CFDEA0E79Q37065678-E83F029B-DD45-423C-A920-C2306DC4E0BFQ37095651-9A415192-ED00-48CF-9ECC-EC1E23407EF8Q37138662-33A69C4D-6EFA-4D78-8365-89713D4565A0Q37369422-89A2B7CF-F904-4315-9589-7BADCC665328Q37475038-91AB14C8-CFB5-4C3F-B811-EA20C868D600Q38400604-2372BF1D-CC25-4B5B-BBA9-3CDB819F7C15Q38746756-761045F6-0526-46AD-A7DC-95E9D6F8DC39Q38919117-948CB271-9C41-402B-B940-7508DE16EA90Q39738488-FEBF1D9B-DB34-4690-8675-93BB07A2C727Q42017054-4B497D20-D8E1-4FE5-B7AF-34FD35E80006Q42644265-8524510A-0E29-4F18-9DD8-F761E6101707Q46861636-EB4963B5-5A3A-4794-AB1E-9DE62B2F62D3Q47098234-50A73143-CC4C-47A6-B30C-DC821A45F764Q47652834-7E2ADEFF-C0A6-43F7-B394-8770A8F43371
P50
name
Katerina Politi
@ast
Katerina Politi
@en
Katerina Politi
@nl
type
label
Katerina Politi
@ast
Katerina Politi
@en
Katerina Politi
@nl
altLabel
K Politi
@en
K. Politi
@en
Politi K
@en
Politi K.
@en
Politi
@en
prefLabel
Katerina Politi
@ast
Katerina Politi
@en
Katerina Politi
@nl
P214
P21
P214
P31
P7859
lccn-n2013048490